IGF1 and acromegaly: In all cohorts, AUC0–28 (area under de curve between days 0–28) and Cmax (maximal concentration) were considerably higher in treatments D and E than in treatments A, B, and C. IGF-I levels were also monitored and remained stable on Day 84 in 3/5 patients (60% of patients with acromegaly who had normal levels at the beginning of the study; 2/3 were in Group D and 1/3 was in Group E).